An Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjects
Latest Information Update: 25 Jun 2025
At a glance
- Drugs DA 5217 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Dong-A ST
Most Recent Events
- 25 Jun 2025 New trial record